Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Colorectal Neoplasms Clinical Trial

— CONCUR  

Official title:

A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Asian Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01584830
• Other study ID #: 15808
• Status: Completed
• Phase: Phase 3
• First received: April 24, 2012
• Last updated: February 5, 2016
• Start date: April 2012
• Est. completion date: January 2016

Study information

• Verified date: February 2016
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug AdministrationHong Kong: Department of HealthTaiwan: Center for Drug EvaluationSouth Korea: Korea Food and Drug Administration (KFDA)Vietnam: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess if Regorafenib in combination with best supportive care will slow down tumor progression and result in increased survival in patients with metastatic colorectal cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 204
• Est. completion date: January 2016
• Est. primary completion date: November 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histological or cytological documentation of adenocarcinoma of the colon or rectum. All other histological types are excluded.

• Subjects with metastatic colorectal cancer(CRC) (Stage IV).

• Subjects must have failed at least two lines of prior treatment.

• Progression during or within 3 months following the last administration of approved standard therapies which must include a fluoropyrimidine, oxaliplatin and irinotecan.

• Subjects treated with oxaliplatin in an adjuvant setting should have progressed during or within 6 months of completion of adjuvant therapy.

• Subjects who progress more than 6 months after completion of oxaliplatin containing adjuvant treatment must be retreated with oxaliplatin-based therapy to be eligible.

• Subjects who have withdrawn from standard treatment due to unacceptable toxicity warranting discontinuation of treatment and precluding retreatment with the same agent prior to progression of disease will also be allowed into the study.

• Subjects may have received prior treatment with Avastin (bevacizumab) and/or Erbitux (cetuximab)/Vectibix (panitumumab) (if KRAS WT)

• Metastatic CRC subjects must have measurable or non measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 1.

• Life expectancy of at least 3 months.

• Adequate bone marrow, liver and renal function as assessed by the laboratory required by protocol.

Exclusion Criteria:

• Prior treatment with Regorafenib.

• Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor invades lamina propria)].

• Extended field radiotherapy within 4 weeks or limited field radiotherapy within 2 weeks prior to randomization.

• Cardiological disease including Congestive heart failure, Unstable angina, Myocardial infarction, Cardiac arrhythmias requiring anti-arrhythmic therapy.

• Uncontrolled hypertension. (Systolic blood pressure 150 mmHg or diastolic pressure 90 mmHg despite optimal medical management).

• Subjects with phaeochromocytoma.

• Pleural effusion or ascites that causes respiratory compromise.

• Arterial or venous thrombotic or embolic events.

• Any history of or currently known brain metastases.

• Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.

• Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 4 week.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Colorectal Neoplasms

Intervention

Drug:
• Regorafenib (BAY73-4506)
Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
• Placebo
Placebo will be given 3 weeks on/1 week off (160 mg od po.)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

China,  Hong Kong,  Korea, Republic of,  Taiwan,  Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact.	From randomization of the first subject untill 154 death events observed, up to 2 years	No
Secondary	Progression-free Survival (PFS)	PFS was defined as the time from date of randomization to disease progression radiological/clinical or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation.	From randomization of the first subject untill 154 death events observed, up to 2 years	No
Secondary	The percentage of subjects with total number of Complete Response (CR) + total number of Partial Response (PR).		From randomization of the first subject untill 154 death events observed, up to 2 years	No
Secondary	Disease Control Rate (DCR)	DCR is defined as the percentage of subjects whose best response was not Progressive Disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of Complete Response (CR) + total number of Partial Response (PR) + total number of Stable Disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating)	From randomization of the first subject untill 154 death events observed, up to 2 years	No
Secondary	Safety variables will be summarized using descriptive statistics based on adverse events collection		From randomization of the first subject untill 154 death events observed, up to 2 years	Yes

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.